Digital Content 
NEWS #PharmaBuzz
02 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/02/3247357/18362/en/Effects-of-Icosapent-Ethyl-on-Risk-and-Duration-of-Hospitalizations-and-Death-in-REDUCE-IT-Post-Hoc-Analysis-Published-in-the-European-Journal-of-Preventive-Cardiology.html
28 Jan 2026
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-28-2026-48857.pdf
09 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/09/3216008/18362/en/Amarin-Applauds-Breakthroughs-In-Therapies-For-Patients-With-Elevated-Triglycerides-Company-s-VASCEPA-VAZKEPA-Icosapent-Ethyl-Franchise-Well-Positioned-To-Benefit-Globally-From-Bro.html
09 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/09/3184162/18362/en/New-REDUCE-IT-Aspirin-Analysis-Presented-at-AHA-Scientific-Sessions-2025-Reinforces-VASCEPA-VAZKEPA-Icosapent-Ethyl-Reduced-Cardiovascular-Events-in-High-Risk-Patients.html
03 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/03/3179271/18362/en/Amarin-To-Present-New-Analyses-Affirming-Robustness-of-Data-from-REDUCE-IT-and-Additional-Mechanisms-of-Action-of-Eicosapentaenoic-Acid-EPA-at-American-Heart-Association-AHA-Scient.html
14 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/14/3166085/18362/en/Amarin-and-HLS-Therapeutics-Collaborate-on-Presenting-REDUCE-IT-and-EPA-Mechanistic-Data-at-the-Canadian-Cardiovascular-Congress.html
Share